Dermapharm Holding SE
DMP
Company Profile
Business description
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
Contact
Lil-Dagover-Ring 7
GrunwaldBY82031
DEUT: +49 89641860
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
3,551
Stocks News & Analysis
stocks
Ask the analyst: Are markets missing something with CSL?
I catch up with Shane Ponraj after an eventful reporting season for healthcare major CSL.
stocks
This ASX stock’s bubble has well and truly burst
Pandemic related tailwinds are a distant memory for Reece, which looks set to face more competition in Australia.
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,231.10 | 2.60 | 0.03% |
| CAC 40 | 7,749.73 | 39.92 | 0.52% |
| DAX 40 | 24,072.74 | 80.13 | -0.33% |
| Dow JONES (US) | 45,449.88 | 31.81 | 0.07% |
| FTSE 100 | 9,249.50 | 16.30 | -0.18% |
| HKSE | 25,201.76 | 323.16 | -1.27% |
| NASDAQ | 21,510.15 | 34.12 | -0.16% |
| Nikkei 225 | 42,520.27 | 125.87 | 0.30% |
| NZX 50 Index | 12,861.84 | 96.14 | -0.74% |
| S&P 500 | 6,462.95 | 2.99 | -0.05% |
| S&P/ASX 200 | 8,960.50 | 0.70 | -0.01% |
| SSE Composite Index | 3,800.35 | 68.03 | -1.76% |